Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/t-l-co-ltd">T&amp;L Co Ltd</a> is a rapidly growing manufacturer of advanced wound care and orthopedic products, capitalizing on its specialized polymer technology. The company has demonstrated exceptional financial performance, with revenue and net income growing at a 3-year CAGR of 34.5% and 33.3%, respectively.</li>
  <li>Despite strong fundamentals, the company's valuation is under pressure due to significant external risks, primarily the threat of potential U.S. tariffs which could impact profitability. This has led to a recent 29% decline in share price and significant net selling by foreign investors.</li>
  <li>Future growth is contingent on the successful execution of its strategic initiatives, which include aggressive expansion into European markets and diversification into new, high-growth product areas like microneedle and cannabis patches.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
T&amp;L Co Ltd is a rapidly growing manufacturer of advanced wound care and orthopedic products, capitalizing on its specialized polymer technology. The company has demonstrated exceptional financial performance, with revenue and net income growing at a 3-year CAGR of 34.5% and 33.3%, respectively.
  Despite strong fundamentals, the company's valuation is under pressure due to significant external risks, primarily the threat of potential U.S. tariffs which could impact profitability. This has led to a recent 29% decline in share price and significant net selling by foreign investors.
  Future growth is contingent on the successful execution of its strategic initiatives, which include aggressive expansion into European markets and diversification into new, high-growth product areas like microneedle and cannabis patches.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: T&L Co Ltd (340570 KS) - Oct 2025

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

<ul>
<li>T&amp;L's key investment highlights include its exceptional sales growth led by its core wound dressing/cosmetic product Mighty Patch.</li>
<li>It had a CAGR sales growth of 44% from 2020 to 2024. Its operating profit increased at even faster rate (CAGR of 56% from 2020 to 2024. </li>
<li>Considering T&amp;L's 40%+ per year sales growth and 50%+ per year operating profit growth from 2020 to 2024 combined with 30%+ ROE, the company is deeply undervalued. </li>
</ul>


T&amp;L's key investment highlights include its exceptional sales growth led by its core wound dressing/cosmetic product Mighty Patch.
It had a CAGR sales growth of 44% from 2020 to 2024. Its operating profit increased at even faster rate (CAGR of 56% from 2020 to 2024. 
Considering T&amp;L's 40%+ per year sales growth and 50%+ per year operating profit growth from 2020 to 2024 combined with 30%+ ROE, the company is deeply undervalued. 


South Korea

T&L Co., Ltd. develops medical polymer material products. Its products include cast, flex, Elasticast, splint, finger splint, and chemical products such as water-borne resin, functional additives, eco-friendly inks, polyurethane foam, and polyurethane elastomer. The company was founded on June 9, 1998 and is headquartered in Yongin-si, South Korea

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

T&L Co Ltd (340570 KS)

Primer: T&L Co Ltd (340570 KS) - Oct 2025

T&L Co Ltd is a rapidly growing manufacturer of advanced wound care and orthopedic products, capitalizing on its specialized polymer...

αSK

Korea Small Cap Gem #42: T&L Co

Considering T&L's 40%+ per year sales growth and 50%+ per year operating profit growth from 2020 to 2024 combined with 30%+ ROE, the company is...

Douglas Kim

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)